Objective To determine whether switching to ticagrelor monotherapy after 3 months of DAPT reduces net adverse clinical events compared with ticagrelor-based 12-month DAPT in patients with ACS treated with drug-eluting stents.ĭesign, Setting, and Participants A randomized multicenter trial was conducted in 3056 patients with ACS treated with drug-eluting stents between August 2015 and October 2018 at 38 centers in South Korea. However, the strategy of ticagrelor monotherapy has not been exclusively evaluated in patients with acute coronary syndromes (ACS). Importance Discontinuing aspirin after short-term dual antiplatelet therapy (DAPT) was evaluated as a bleeding reduction strategy. Shared Decision Making and Communication.Scientific Discovery and the Future of Medicine.Health Care Economics, Insurance, Payment.Clinical Implications of Basic Neuroscience.Challenges in Clinical Electrocardiography. Subgroup Analyses for Major Adverse Cardiac and Cerebrovascular Event Subgroup Analyses for Major BleedingĮFigure 3. Per-Protocol and As-Treated Analyses for the Net Adverse clinical EventsĮFigure 2. Per-Protocol and As-Treated Analyses for Clinical OutcomesĮFigure 1. Patient, Lesion, and Procedural Characteristics for the As-Treated PopulationĮTable 12. Patient, Lesion, and Procedural Characteristics for the Per-Protocol PopulationĮTable 11. Bleeding Events According to the Bleeding Academic Research Consortium DefinitionĮTable 10. Angiographic and Procedural CharacteristicsĮTable 7. Reasons for Nonadherence to the Allocated TreatmentĮTable 6. Antiplatelet Therapy During Study PeriodĮTable 5. Days From Percutaneous Coronary Intervention to RandomizationĮTable 4. Bleeding Definition According to the Bleeding Academic Research ConsortiumĮTable 3. Inclusion and Exclusion CriteriaĮTable 2.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |